Multi-centre clinical study evaluating the efficacy of SonoVue™ (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions

Leen, Edward; Angerson, Wilson J.; Yarmenitis, Spyros; Bongartz, G.; Blomley, Martin; Maschio, Alessandro Del; Summaria, Vincenzo; Maresca, G; Pezzoli, C; Llull, J.B.

doi:10.1016/s0720-048x(01)00457-0

Cited by 108 publications

(57 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, we used SonoVue, a second-generation ultrasound contrast agent. SonoVue is an intravascular agent (Leen et al 2002) and the mechanism underlying liver parenchymal enhancement remains unknown (Leen et al 2006). It has been suggested that the persistence of the agent within the healthy liver may be a result of the very slow flow within the sinusoids (Leen et al 2006).…”

Section: Discussionmentioning

confidence: 99%

“…SonoVue (Bracco Imaging, Milan, Italy) is an intravascular ultrasound contrast agent that consists of stabilized microbubbles of a sulfur hexafluoride gas (Leen et al 2002). Experimental evidence in rats has shown that microbubble agents containing perfluorocarbon gas, such as SonoVue, enhance the healthy liver by virtue of its slow flow within the sinusoids (Kono et al 2002).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liver Contrast Enhanced Ultrasound Perfusion Imaging in the Evaluation of Chronic Hepatitis C Fibrosis: Preliminary Results

Orlacchio

Bolacchi

Petrella

et al. 2011

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

Abstract-We wanted to determine whether liver contrast-enhanced ultrasound (CEUS)-derived peak signal intensity (PSI) and peak signal intensity/time (PIT) predict liver fibrosis in chronic hepatitis C (CHC). Fortynine patients with CHC (METAVIR classification) and 10 control subjects were included in the study. After a bolus of 2.4 mL SonoVue (Bracco Imaging, Milan, Italy) solution was injected into a peripheral vein, the right lobe of the liver containing the right portal vein was scanned in a transverse section. Two-dimensional sonography was performed using the Philips iU22 ultrasound system (Philips Healthcare, Best, the Netherlands). A 1.0-5.0-MHz (C5-1) wideband convex transducer was used, applying the following settings in all cases. Regions of interest were manually drawn over the right liver lobe and over the portal vein (PV). Liver parenchyma PSI (LPpsi) and PIT (LPpit), portal vein PSI (PVpsi) and PIT (PVpit) were automatically calculated. dPSI was defined as the difference between PVpsi and LPpsi. A significant correlation was observed between PA PSI and fibrosis scores. When patients were stratified according to their LPpsi, a significant difference was achieved only between patients with fibrosis score 0-1 vs. 2-3 and 2 vs. 4. Statistically significant differences between all fibrosis scores, except 0 vs. 1 and 3 vs. 4 were observed when dPSI was used to stratify patients. Overall diagnostic accuracy of LPpsi and dPSI measurement for severe fibrosis by area under the receiving operator characteristic curve analysis was, respectively, 0.87 and 0.88. We suggest that liver CEUS perfusion could have the potential to be used as a complementary tool for the evaluation of liver fibrosis. However, further large-scale studies are required to accurately assess its accuracy in the evaluation of liver fibrosis. (E-mail: aorlacchio@uniroma2.it) Ó 2011 World Federation for Ultrasound in Medicine & Biology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Liver Contrast Enhanced Ultrasound Perfusion Imaging in the Evaluation of Chronic Hepatitis C Fibrosis: Preliminary Results

Orlacchio

Bolacchi

Petrella

et al. 2011

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

show abstract

“…Recent studies have evaluated the revenue of enhanced Doppler in differentiating benign from malignant hepatic lesions 25 and breast tumours. 26 Further research should be performed to investigate the diagnostic accuracy of contrast-enhanced Doppler ultrasound in differentiating benign from malignant SG tumours compared with the baseline (pre-dosing) performance.…”

Section: Pulsatility Indexmentioning

confidence: 99%

A prospective study of three diagnostic sonographic methods in differentiation between benign and malignant salivary gland tumours

El-Khateeb

Abou-Khalaf²,

Farid³

et al. 2011

Dentomaxillofacial Radiology

View full text Add to dashboard Cite

“…The microbubbles are isotonic to human plasma and stable and resistant to pressure. SonoVue improves the display of focal tumor vascularity and normal parenchymal liver vascularity [16] . Sonazoid is another second-generation UCA solely available in Japan.…”

Section: Ultrasound Contrast Agents (Ucas) and Contrast-specific Techmentioning

confidence: 99%

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Wong

Xu²,

Xie³

2009

WJR

View full text Add to dashboard Cite

Patients with liver cirrhosis are at increased risk of hepatocellular carcinoma (HCC). Conventional or baseline ultrasound (BUS) is often used as the first-line tool for HCC surveillance or detection, but the accuracy of BUS in HCC detection or differentiation from other focal liver lesions (FLLs) is limited. Contrast-enhanced ultrasound (CEUS) represents a recent revolution in the field of ultrasonography and it has become increasingly important in the detection and evaluation of FLLs. In CEUS, HCC typically exhibits arterial hyper-enhancement and portal-venous washout represented by hypoenhanced lesions in the portal venous and late phases. The detection rate of HCC was significantly higher with CEUS compared with BUS. Even regenerative or some dysplastic nodules may exhibit arterial hyperenhancement as they are differentiated from HCC by its iso-enhancing pattern in portal and late phases. The contrast-enhancement patterns of other different types of benign and malignant FLLs, as well as their detection rates with CEUS, were also discussed.

show abstract

Multi-centre clinical study evaluating the efficacy of SonoVue™ (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions

Cited by 108 publications

References 11 publications

Liver Contrast Enhanced Ultrasound Perfusion Imaging in the Evaluation of Chronic Hepatitis C Fibrosis: Preliminary Results

Liver Contrast Enhanced Ultrasound Perfusion Imaging in the Evaluation of Chronic Hepatitis C Fibrosis: Preliminary Results

A prospective study of three diagnostic sonographic methods in differentiation between benign and malignant salivary gland tumours

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Contact Info

Product

Resources

About